Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir

• Yu Bai,
• Fei Ye,
• Yong Feng,
• Hanyi Liao,
• Hao Song,
• Jianxun Qi,
• George Fu Gao,
• Wenjie Tan,
• Lifeng Fu,
• Yi Shi

Affiliations

Yu Bai

Savaid Medical School, University of Chinese Academy of Sciences

Fei Ye

NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control & Prevention, Chinese Center for Disease Control and Prevention, China CDC

Yong Feng

Savaid Medical School, University of Chinese Academy of Sciences

Hanyi Liao

Savaid Medical School, University of Chinese Academy of Sciences

Hao Song

Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences

Jianxun Qi

Savaid Medical School, University of Chinese Academy of Sciences

George Fu Gao

Savaid Medical School, University of Chinese Academy of Sciences

Wenjie Tan

Research Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences

Lifeng Fu

CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences

Yi Shi

Savaid Medical School, University of Chinese Academy of Sciences